血清癌胚抗原、糖类抗原125、血管内皮生长因子联合检测在肺癌同步放化疗疗效评估中的临床价值

Clinical Value of Joint detection of Serum Carcinoembryonic Antigen,Carbohydrate Antigen125,Vascular Endothelial Growth Factor in the Curative effect evaluation of Concurrent Radiotherapy in the Treatment of Non-small Cell Lung Cancer

目的探讨血清癌胚抗原(CEA)、糖类抗原125(CA125)、血管内皮生长因子(VEGF)联合检测在非小细胞肺癌同步放化疗疗效评估中的临床价值。方法选取40例Ⅲ期非小细胞肺癌患者,测定同步放化疗前后血清CEA、CA125、VEGF水平,并以20例健康志愿者作对照。同时比较观察疗效与血清CEA、CA125、VEGF水平的关系。结果非小细胞肺癌患者同步放化疗前血清CEA、CA125及VEGF水平均明显高于健康志愿者,差异均有统计学意义(P均<0.05)。疗效评价结果显示,有效25例(CR 5例,PR 20例),无效15例(SD 7例,PD 8例),有效组治疗后血清CEA、CA125及VEGF水平均明显降低,差异有统计学意义(P均<0.05);无效组治疗后血清CEA、CA125及VEGF水平无明显变化(P>0.05)。结论血清CEA、CA125、VEGF水平变化可作为肺癌同步放化疗临床疗效评估的指标之一。

Objective To discuss the clinical value of joint detection of serum earcinoembryonic antigen （CEA）, carbohydrate antigen 125 （CA125）, vascular endothelial growth factor （VEGF） in the curative effect evalu- ation of concurrent radiotherapy in the treatment of non-small cell lung cancer. Methods Serum CEA, CA125, VEGF levels were detected before and after concurrent chemoradiotherapy in the 40 patients with non-small cell lung cancer, and 20 cases of healthy volunteers were studied as the controls. The relationship between curative effect and serum CEA, CA125, VEGF levels were analyzed. Results Before concurrent chemoradiotherapy, the serum CEA, CA125, VEGF levels in the patients with non-small cell lung cancer were higher than those in the healthy volunteers （ P 〈 0.05）. Twenty-five patients （ CR 5 patients, PR 20 patients） were effect, and 15 patients （ SD 7 patients, PD 8 patients） were no effect. In the effect group,the serum CEA, CA125, VEGF levels after concurrent chemoradiothera- py, were lower than those before concurrent chemoradiotherapy （ P 〈 0.05 ）. In the no effect group, there was no sta- tistical difference before and after concurrent chemoradiotherapy （P 〉 0.05 ）. Conclusion Serum CEA, CA125 and VEGF levels can be used as the indicator in the curative effect evaluation of concurrent radiotherapy in the treatmentof non-small cell lung cancer.